Press Releases

Carevive Awarded National Cancer Institute SBIR Fast-Track to Advance Symptom Management Clinical Decision Support Technology

By June 12, 2020June 26th, 2020No Comments
Carevive Awarded National Cancer Institute SBIR Fast-Track to Advance Symptom Management Clinical Decision Support Technology

NCI awards Carevive with the only Fast-Track Phase I/II contract supporting the development of an innovative symptom management and electronic patient-reported outcome solution

North Miami, Florida —June 26, 2020 — Carevive, a health technology company that builds cancer care management and patient engagement solutions to improve patient quality of life and clinical outcomes, announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) in response to a call for proposals under a contract topic entitled “Bridging the Guideline Implementation Gap: Clinical Decision-Support to Improve Cancer Symptom Management”.

Carevive was awarded Phase I in September 2018 and after successful completion, Phase II was awarded.

The contract is supporting the development of an electronic interoperable clinical decision support (CDS) tool for cancer-related symptom assessment and management.

This technology leverages Carevive PROmpt®, the company’s electronic patient-reported outcomes (ePRO) tool for symptom monitoring with current evidence-based guidelines and its interoperable clinical patient data to deliver personalized, evidence-based symptom management pathways. The user interface will be built based on insights from patients with cancer to ensure a positive patient experience. Carevive is the only company that applied for and received a Fast-Track Phase I/II contract award under this particular research topic.

“We are very pleased to receive this award from the NCI,” said Dr. Debra Wujcik, Carevive’s VP, Research & Clinical Operations and the SBIR contract’s principal investigator. “In Phase I, we demonstrated the ability to develop evidence-based symptom management guidelines into computable decision support for front line caregivers. Patients experiencing side effects of cancer treatment can report their experience using their telephone or other mobile device. The health care staff can further assess the symptom and provide prompt instruction to help the patient relieve their symptoms. Ultimately, proactive symptom management keeps the patient from making extra visits to the provider, emergency department, or hospital. During Phase II, we will complete the CDS suite of most common symptoms and incorporate it into our product platform.”

Madelyn Trupkin Herzfeld, Founder and CEO of Carevive also commented, “Through this SBIR opportunity we were also selected to participate in the NCI SBIR Investor Initiatives in 2019. We received NCI SBIR support to attend RESI, where we met our latest strategic investor, Debiopharm Innovation Fund. Debiopharm is a biopharmaceutical company with an ongoing commitment to improve patient outcomes and quality of life in oncology, with a focus on drug development, drug manufacturing and digital health. Debiopharm is working closely with Carevive to build our life science business.”

The CDS tools developed in this project will build upon the Carevive ePRO platform and rules-based Carevive clinical intelligence system (CIS) that, since 2014, has both been extensively tested for feasibility, usability, and utility in over 37 cancer programs, as well as commercially used in over a dozen cancer centers for patient monitoring and personalized self-management of symptoms and other patient-reported outcomes.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800021C.

About Carevive


Carevive Systems, founded in 2013, is an oncology-focused health technology company dedicated to understanding and improving the cancer patient experience. Our platform enables providers to deliver better quality cancer care, and patients to be more engaged in their treatment, which will improve survival outcomes. Use of Carevive in the clinic unlocks critical data on the real-world cancer patient experience to continuously improve patient care today and provide better access to novel therapies in the future.

For more information, please visit https://www.carevive.com or follow us @carevive.